ReviewFrontiers in neurology2018
Neuroprotection in Traumatic Brain Injury: Mesenchymal Stromal Cells can Potentially Overcome Some Limitations of Previous Clinical Trials.
Review in Frontiers in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163833 (MATRIx), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MATRIx: MesenchymAl Stromal Cells for Traumatic bRain Injury
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolution of mesenchymal stem cell therapies for traumatic brain injury: A decade of advances, mechanisms, and translational prospects.Cell transplantationPooled it
- Injectable Supramolecular Hydrogel Encapsulating CRISPR-Engineered MSCs Drives Synergistic Neuroprotection and Functional Recovery After Traumatic Brain Injury.Advanced healthcare materials · 2026Article
- Trans-septal delivery of hydrogel-encapsulated human umbilical cord MSC-derived neurospheres for acute neuroprotection in traumatic brain injury.APL bioengineering · 2026Article
- 3D printing of interferon γ-preconditioned NSC-derived exosomes/collagen/chitosan biological scaffolds for neurological recovery after TBI.Bioactive materials · 2024Article
- The application of mesenchymal stem cells in the treatment of traumatic brain injury: Mechanisms, results, and problems.Histology and histopathology · 2024Review
- Regulatory T lymphocytes in traumatic brain injury.Neurochemistry international · 2024Review
- MesenchymAl stromal cells for Traumatic bRain Injury (MATRIx): a study protocol for a multicenter, double-blind, randomised, placebo-controlled phase II trial.Intensive care medicine experimental · 2023Article
- Injectable hyaluronic acid hydrogel loaded with BMSC and NGF for traumatic brain injury treatment.Materials today. Bio · 2022Article
- Propofol effects in rodent models of traumatic brain injury: a systematic review.Asian biomedicine : research, reviews and news · 2021Article
- Systematic review and meta-analysis of preclinical studies testing mesenchymal stromal cells for traumatic brain injury.NPJ Regenerative medicine · 2021Article
- Novel Synthetic and Natural Therapies for Traumatic Brain Injury.Current neuropharmacology · 2021Review
- Hypoxic preconditioning enhances the differentiation of bone marrow stromal cells into mature oligodendrocytes via the mTOR/HIF-1α/VEGF pathway in traumatic brain injury.Brain and behavior · 2020Article
- Potential of mesenchymal stem cells alone, or in combination, to treat traumatic brain injury.CNS neuroscience & therapeutics · 2020Review
- Acupuncture for hearing loss after traumatic brain injury: A protocol for systematic review of randomized controlled trial.Medicine · 2019Article
- The role of long noncoding RNA in traumatic brain injury.Neuropsychiatric disease and treatment · 2019Review
- The potential roles of dopamine in traumatic brain injury: a preclinical and clinical update.American journal of translational research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. In the last 30 years several neuroprotective agents, attenuating the downstream molecular and cellular damaging events triggered by TBI, have been extensively studied. Even though many drugs have shown promising results in the pre-clinical stage, all have failed in large clinical trials. Mesenchymal stromal cells (MSCs) may offer a promising new therapeutic intervention, with preclinical data showing protection of the injured brain. We selected three of the critical aspects identified as possible causes of clinical failure: the window of opportunity for drug administration, the double-edged contribution of mechanisms to damage and recovery, and the oft-neglected role of reparative mechanisms. For each aspect, we briefly summarized the limitations of previous trials and the potential advantages of a newer approach using MSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.